| HLA‐DQB1 and‐DQA1 typing by PCR amplification with sequence‐specific primers (PCR‐SSP) in 2 hours O Olerup, A Aldener, A Fogdell Tissue antigens 41 (3), 119-134, 1993 | 775 | 1993 |
| Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies G Luna, P Alping, J Burman, K Fink, A Fogdell-Hahn, M Gunnarsson, ... JAMA neurology 77 (2), 184-191, 2020 | 433 | 2020 |
| Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease A Fogdell‐Hahn, A Ligers, M Grønning, J Hillert, O Olerup Tissue antigens 55 (2), 140-148, 2000 | 322 | 2000 |
| HLA-DR predicts the prognosis in Scandinavian patients with pulmonary sarcoidosis M Berlin, A Fogdell-Hahn, O Olerup, A Eklund, J Grunewald American journal of respiratory and critical care medicine 156 (5), 1601-1605, 1997 | 317 | 1997 |
| Detection of human herpesvirus-6 in mesial temporal lobe epilepsy surgical brain resections D Donati, N Akhyani, A Fogdell–Hahn, C Cermelli, R Cassiani-Ingoni, ... Neurology 61 (10), 1405-1411, 2003 | 266 | 2003 |
| Association of human herpesvirus-6B with mesial temporal lobe epilepsy J Fotheringham, D Donati, N Akhyani, A Fogdell-Hahn, A Vortmeyer, ... PLoS Medicine 4 (5), e180, 2007 | 187 | 2007 |
| Differential tropism of human herpesvirus 6 (HHV-6) variants and induction of latency by HHV-6A in oligodendrocytes J Ahlqvist, J Fotheringham, N Akhyani, K Yao, A Fogdell-Hahn, ... Journal of neurovirology 11 (4), 384-394, 2005 | 140 | 2005 |
| A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis C Holmén, F Piehl, J Hillert, A Fogdell-Hahn, M Lundkvist, E Karlberg, ... Multiple Sclerosis Journal 17 (6), 708-719, 2011 | 122 | 2011 |
| Cancer risk for fingolimod, natalizumab, and rituximab in multiple sclerosis patients P Alping, J Askling, J Burman, K Fink, A Fogdell‐Hahn, M Gunnarsson, ... Annals of neurology 87 (5), 688-699, 2020 | 101 | 2020 |
| Rituximab in multiple sclerosis: frequency and clinical relevance of anti-drug antibodies N Dunn, A Juto, M Ryner, A Manouchehrinia, L Piccoli, K Fink, F Piehl, ... Multiple Sclerosis Journal 24 (9), 1224-1233, 2018 | 100 | 2018 |
| Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines … Clinical & Experimental Immunology 181 (3), 385-400, 2015 | 82 | 2015 |
| Increased serological response against human herpesvirus 6A is associated with risk for multiple sclerosis E Engdahl, R Gustafsson, J Huang, M Biström, I Lima Bomfim, P Stridh, ... Frontiers in Immunology 10, 2715, 2019 | 78 | 2019 |
| Changes to anti-JCV antibody levels in a Swedish national MS cohort C Warnke, R Ramanujam, T Plavina, T Bergström, S Goelz, ... Journal of Neurology, Neurosurgery & Psychiatry 84 (11), 1199-1205, 2013 | 76 | 2013 |
| Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a AK Hedström, M Ryner, K Fink, A Fogdell-Hahn, L Alfredsson, T Olsson, ... Multiple Sclerosis Journal 20 (4), 445-450, 2014 | 73 | 2014 |
| Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity A Sominanda, U Rot, M Suoniemi, F Deisenhammer, J Hillert, ... Multiple Sclerosis Journal 13 (2), 208-214, 2007 | 73 | 2007 |
| In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent A Sominanda, J Hillert, A Fogdell-Hahn Journal of Neurology, Neurosurgery & Psychiatry 79 (1), 57-62, 2008 | 72 | 2008 |
| Elevated serum and cerebrospinal fluid levels of soluble human herpesvirus type 6 cellular receptor, membrane cofactor protein, in patients with multiple sclerosis SS Soldan, A Fogdell‐Hahn, MB Brennan, BB Mittleman, C Ballerini, ... Annals of Neurology: Official Journal of the American Neurological …, 2001 | 68 | 2001 |
| Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab PS Sørensen, PE Hyldgaard Jensen, A Haghikia, M Lundkvist, C Vedeler, ... Multiple Sclerosis Journal 17 (9), 1074-1078, 2011 | 66 | 2011 |
| Smokers run increased risk of developing anti-natalizumab antibodies AK Hedström, L Alfredsson, M Lundkvist Ryner, A Fogdell-Hahn, J Hillert, ... Multiple Sclerosis Journal 20 (8), 1081-1085, 2014 | 65 | 2014 |
| JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants E Sundqvist, D Buck, C Warnke, E Albrecht, C Gieger, M Khademi, ... PLoS pathogens 10 (4), e1004084, 2014 | 65 | 2014 |
